On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical company based in Guangzhou, China, announced that it has recently signed a licensing and commercialization agreement with World Medicine for BAT2206. BAT2206 is a biosimilar developed based on Stelara® (ustekinumab).
Agreement Details
Under the agreement, World Medicine will have exclusive distribution and sales rights for BAT2206 in the Turkish market and will be responsible for the introduction, registration, and sales of BAT2206 in Turkey. Bio-Thera Solutions will be in charge of the research, production, and commercial supply of BAT2206. Currently, the marketing authorization application for BAT2206 has been accepted by China’s NMPA, the US FDA, and the European EMA.-Fineline Info & Tech
